Rabbit Polyclonal MOX1(Meox1)(N-term) Antibody

+ +

•  

   
     Anti-Meox1 (Human N-term) at 1:1000 dilution + human heart lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 28 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Western blot analysis of anti-Meox1 Antibody (N-term) (Cat. #P33577) in 293 cell line lysates (35ug/lane). Meox1(arrow) was detected using the purified Pab.    

•  

   
     Fluorescent confocal image of Hela cell stained with Meox1 (Human N-term)(Cat#P33577).Hela cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with Meox1 primary antibody (1:25, 1 h at 37℃). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used (1:400, 50 min at 37℃).Cytoplasmic actin was counterstained with Alexa Fluor® 555 (red) conjugated Phalloidin (7units/ml, 1 h at 37℃). Nuclei were counterstained with DAPI (blue) (10 µg/ml, 10 min). Meox1 immunoreactivity is localized to Nucleolus significantly.    

The MOX1 (Meox1) (N-term) antibody is a tool used to detect the N-terminal region of the Mesenchyme Homeobox 1 (Meox1) protein, a transcription factor belonging to the homeobox gene family. Meox1. also known as MOX1. plays critical roles in embryonic development, particularly in mesoderm-derived tissues. It regulates processes such as somitogenesis, myogenesis, and vascular development by binding to DNA via its homeodomain to control gene expression. During embryogenesis, Meox1 is essential for skeletal muscle differentiation and patterning, as well as the development of mesenchymal tissues. In adults, it is expressed in skeletal muscle, heart, and other mesodermal derivatives, where it may influence tissue maintenance and repair.

The antibody is commonly used in research applications like Western blotting, immunohistochemistry, and immunofluorescence to study Meox1 expression, localization, and function. Its specificity for the N-terminal region ensures recognition of full-length or truncated isoforms, aiding in investigations of Meox1’s role in developmental disorders, muscular dystrophies, or cancer, where its dysregulation has been implicated. Validation typically includes testing in Meox1-deficient models or siRNA-treated cells to confirm target specificity. Researchers rely on this antibody to explore Meox1’s interactions with signaling pathways (e.g., Wnt or TGF-β) and its potential as a biomarker or therapeutic target in diseases involving aberrant mesodermal differentiation or tissue homeostasis.